Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings

BACKGROUND: Abacavir and rilpivirine are alternative antiretroviral drugs for treatment-naïve HIV-infected patients. However, both drugs are only recommended for the patients who have pre-treatment HIV RNA <100,000 copies/mL. In resource-limited settings, pre-treatment HIV RNA is not routinely pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiertiburanakul, Sasisopin, Boettiger, David, Ng, Oon Tek, Van Kinh, Nguyen, Merati, Tuti Parwati, Avihingsanon, Anchalee, Wong, Wing-Wai, Lee, Man Po, Chaiwarith, Romanee, Kamarulzaman, Adeeba, Kantipong, Pacharee, Zhang, Fujie, Choi, Jun Yong, Kumarasamy, Nagalingeswaran, Ditangco, Rossana, Cuong, Do Duy, Oka, Shinichi, Sim, Benedict Lim Heng, Ratanasuwan, Winai, Ly, Penh Sun, Yunihastuti, Evy, Pujari, Sanjay, Ross, Jeremy L., Law, Matthew, Sungkanuparph, Somnuek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420083/
https://www.ncbi.nlm.nih.gov/pubmed/28484509
http://dx.doi.org/10.1186/s12981-017-0151-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420083/
https://www.ncbi.nlm.nih.gov/pubmed/28484509
http://dx.doi.org/10.1186/s12981-017-0151-1

Ejemplares similares